A Quantum Leap For IOLS
Setting a new standard in monofocal IOLs thanks to innovative enhancement using QUANTUM optical technology
sponsored by Teleon
Cataract and refractive surgery patient expectations are at an all-time high, so it is important that doctors have the finest devices available to help patients achieve the best vision possible. An IOL that gives the patient the best and most accurate refractive outcomes, and a better functional vision for intermediate ranges following standard cataract surgery is a game changer in this field – and Teleon Surgical ticks all these boxes with the LENTIS QUANTUM.
The LENTIS QUANTUM enhanced monofocal IOL represents a substantial leap in monofocal IOL technology. How? By mimicking EDoF technology for improved intermediate vision, but also by ensuring a low chance of photic phenomena. This refining innovation represents a new standard in monofocal IOL design and addresses the increasing patient demand for improved outcomes following standard cataract treatment.
The Q-zone optic design is the secret sauce that gives patients improved intermediate vision. In effect, this Q-zone mimics an extended range of focus but, because a progressive surface profile is used, there is no interruption of light focusing on the retina, as there would be with a multifocal or trifocal design. Thanks to this innovative optic concept, surgeons have the opportunity to provide patients with better refractive results and functional vision compared with aspheric monofocal IOLs.
The QUANTUM optic technology will be made available on various IOL platforms, as well as toric models, to address patients requiring astigmatism correction – and will enable Teleon Surgical to continue defining the IOL space in the future. The platform – recently launched at the ESCRS 2021 conference in Amsterdam – is available in a range between 10.0 D and 30.0 D in 0.5 D increments.
Now popular with an increasing number of surgeons globally, the LENTIS QUANTUM IOL addresses increasing patient demands to achieve better outcomes in the standard range of monofocal cataract treatments.